Klaus Ochmann

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
UNLABELLED Biomarkers are increasingly used to provide decision making data early in phase I by showing Proof of Mechanism or Proof of Concept (PoM/PoC). For antihypertensive agents, the administration of multiple doses (md) to hypertensive patients is assumed to be necessary for an early go/no-go decision. We compared the effects of an Angiotensin II(More)
  • 1